JP2019530718A - ゲムシタビンのＴＰＣＳ−２ａ誘導性光化学的内在化を用いた胆管癌の処置 - Google Patents

ゲムシタビンのＴＰＣＳ−２ａ誘導性光化学的内在化を用いた胆管癌の処置 Download PDF

Info

Publication number
JP2019530718A
JP2019530718A JP2019519974A JP2019519974A JP2019530718A JP 2019530718 A JP2019530718 A JP 2019530718A JP 2019519974 A JP2019519974 A JP 2019519974A JP 2019519974 A JP2019519974 A JP 2019519974A JP 2019530718 A JP2019530718 A JP 2019530718A
Authority
JP
Japan
Prior art keywords
gemcitabine
tpcs
treatment
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019519974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530718A5 (enExample
Inventor
ホッグセット、アンダース
ワルデイ、ペール、エドヴァルド
セルボ、パル、クリスチャン
エイヴィンドヴィク、クリスティン
フィンネサンド、レナ
Original Assignee
ピーシーアイ バイオテック エイエス
ピーシーアイ バイオテック エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617526.7A external-priority patent/GB201617526D0/en
Priority claimed from GBGB1704719.2A external-priority patent/GB201704719D0/en
Application filed by ピーシーアイ バイオテック エイエス, ピーシーアイ バイオテック エイエス filed Critical ピーシーアイ バイオテック エイエス
Publication of JP2019530718A publication Critical patent/JP2019530718A/ja
Publication of JP2019530718A5 publication Critical patent/JP2019530718A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019519974A 2016-10-14 2017-10-13 ゲムシタビンのＴＰＣＳ−２ａ誘導性光化学的内在化を用いた胆管癌の処置 Pending JP2019530718A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1617526.7A GB201617526D0 (en) 2016-10-14 2016-10-14 Method
GB1617526.7 2016-10-14
GB1704719.2 2017-03-24
GBGB1704719.2A GB201704719D0 (en) 2017-03-24 2017-03-24 Method
PCT/EP2017/076257 WO2018069536A1 (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Publications (2)

Publication Number Publication Date
JP2019530718A true JP2019530718A (ja) 2019-10-24
JP2019530718A5 JP2019530718A5 (enExample) 2020-11-26

Family

ID=60186250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519974A Pending JP2019530718A (ja) 2016-10-14 2017-10-13 ゲムシタビンのＴＰＣＳ−２ａ誘導性光化学的内在化を用いた胆管癌の処置

Country Status (13)

Country Link
US (1) US20200338044A1 (enExample)
EP (1) EP3525783B1 (enExample)
JP (1) JP2019530718A (enExample)
KR (1) KR20190068573A (enExample)
CN (1) CN110022874A (enExample)
AU (1) AU2017342086A1 (enExample)
CA (1) CA3040344A1 (enExample)
DK (1) DK3525783T3 (enExample)
ES (1) ES2841941T3 (enExample)
PL (1) PL3525783T3 (enExample)
RU (1) RU2019109682A (enExample)
SG (1) SG11201903057XA (enExample)
WO (1) WO2018069536A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507383A (ja) * 2001-08-30 2005-03-17 ピーシーアイ バイオテック エイエス 化合物
WO2011018635A2 (en) * 2009-08-14 2011-02-17 Pci Biotech As Photosensitizing compositions
WO2011018636A2 (en) * 2009-08-14 2011-02-17 Pci Biotech As Photochemical internalization method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
CN100558903C (zh) 2000-11-29 2009-11-11 Pci生物技术联合股份有限公司 将分子输递进胞质溶胶的光化学内化法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507383A (ja) * 2001-08-30 2005-03-17 ピーシーアイ バイオテック エイエス 化合物
WO2011018635A2 (en) * 2009-08-14 2011-02-17 Pci Biotech As Photosensitizing compositions
WO2011018636A2 (en) * 2009-08-14 2011-02-17 Pci Biotech As Photochemical internalization method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIAL.GOV ARCHIVE, HISTORY OF CHANGES FOR STUDY: NCT01900158, SUBMITTED DATE: OCTOBER 12, 20, JPN6021032414, ISSN: 0004914914 *
HEAD & NECK ONCOLOGY, vol. 2(Suppl 1):O44, JPN6021032418, 2010, ISSN: 0004576446 *
HTTPS://OCCINNOVATIONPARK.COM/POSITIVE-RESULTS-ON-BILE-DUCT-CANCER-FROM-PCI-BIOTECH/［検索日：２０２, JPN6021032416, ISSN: 0004576444 *
INT. J. CANCER, vol. 138, JPN6021032417, 10 March 2015 (2015-03-10), pages 1049 - 1057, ISSN: 0004576445 *
LANCET ONCOL, vol. 17, JPN6021032413, 2016, pages 1217 - 1229, ISSN: 0004576448 *
PHOTOCHEM. PHOTOBIOL. SCI., vol. 10, JPN6021032412, 2011, pages 1637 - 1651, ISSN: 0004576447 *

Also Published As

Publication number Publication date
EP3525783A1 (en) 2019-08-21
DK3525783T3 (da) 2021-01-18
SG11201903057XA (en) 2019-05-30
US20200338044A1 (en) 2020-10-29
ES2841941T3 (es) 2021-07-12
AU2017342086A1 (en) 2019-05-09
PL3525783T3 (pl) 2021-04-19
KR20190068573A (ko) 2019-06-18
RU2019109682A3 (enExample) 2021-02-15
CA3040344A1 (en) 2018-04-19
CN110022874A (zh) 2019-07-16
EP3525783B1 (en) 2020-12-16
WO2018069536A1 (en) 2018-04-19
RU2019109682A (ru) 2020-11-16

Similar Documents

Publication Publication Date Title
Spring et al. The role of photodynamic therapy in overcoming cancer drug resistance
Zelefsky et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer
Aebisher et al. The use of photodynamic therapy in medical practice
Crescenzi et al. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
Ogata et al. Near-infrared photoimmunotherapy: a comparison of light dosing schedules
CN111343984A (zh) 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物
JP2019530718A (ja) ゲムシタビンのＴＰＣＳ−２ａ誘導性光化学的内在化を用いた胆管癌の処置
CA2729369A1 (en) Photochemical internalization of kinase inhibitors
Cheon Recent advances of photodynamic therapy for biliary tract cancer
Sun et al. Light dose effect of photodynamic therapy on growth inhibition and apoptosis induction in non-small cell lung cancer: A study in nude mouse model
US20210283255A1 (en) Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation
Murphy et al. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma
ES3017257T3 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
CA2557857C (en) Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
Magné et al. Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development
TWI434829B (zh) 以密環菌乙素來治療癌症之新穎用途
US20210205289A1 (en) Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
園川卓海 et al. Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate
Sardi et al. Drug penetration through the blood–brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance
Hong et al. PD43-02 THERAPEUTIC EFFICACY OF YM155 TO REPRESS AN EPIGENETIC ENZYME AND EVEROLIMUS RESISTANCE IN RCC
KR20250105657A (ko) 카피바설팁과 베네토클락스의 치료적 조합
EP4259132A1 (en) Methods for treating cutaneous metastatic cancers
Ng Bioluminescence-Mediated Photodynamic Therapy: A Novel Treatment for Grade 4 Astrocytoma
RICHARD et al. Research Reports and Clinical Perspective
Braakhuisa et al. Chk1 Inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221108